CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula,

The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most at-risk Americans this fall.

Despite the fact that vaccines against COVID have already undergone strict safety reviews and that people continue to die from the disease, Trump’s FDA is moving to reduce access to annual COVID boost